In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inter Partes Review Petitions Pile Up

Executive Summary

A list of biopharma IPR petitions by category.

You may also be interested in...



New Patent Battleground: Inter Partes Reviews Besiege Innovators

Inter partes review, a new patent challenge proceeding, is increasingly being deployed against biopharma companies by generic manufacturers, biosimilar sponsors and hedge fund manager Kyle Bass. What the industry is doing to fight back.

BioMarin Clears Path For Pompe Treatment After Knocking Out Genzyme Patents

Genzyme’s Myozyme patents invalid for being obvious, Patent Trial and Appeal Board finds in inter partes review.

QUOTED. 8 July 2020. Stephen Hahn.

BD Diagnostics has gained emergency use authorization (EUA) for a handheld rapid COVID-19 antigen test that could play a pivotal role in fighting an ongoing surge of coronavirus outbreaks. See what US FDA commissioner Stephen Hahn said about it here.

Topics

UsernamePublicRestriction

Register

LL1132940

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel